Epoetin Beta Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Epoetin Beta Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

  • Transparency Market Research
  • Ongoing
  • Pharmaceutical

Report Description

1
1

Erythropoietin is a hormone released from the kidneys. Erythropoietin protein is responsible for the development of red blood cells (RBCs) in the body. Increase in the number of RBCs raises the level of hemoglobin in the blood, which is the substance responsible for transport of oxygen to every part of the body. Epoetin beta is one of the three erythropoiesis-stimulating agents available in the epoetin beta therapeutics market. It is used for the treatment of anemia in patients with severe kidney disease. Epoetin beta is given in combination with methoxy polyethylene glycol. One of the most common complications of chronic kidney disease is anemia. Its rate of prevalence with CKD is twice than the prevalence rate in the general population. Also, the rate of prevalence of anemia increased rapidly from stage 1 (8.4%) to stage 5 (53.4%) of CKD.

The epoetin beta therapeutics market is expected to expand rapidly during the forecast period, owing to factors such as increase in the prevalence of chronic kidney disease, increased returns on investment (RoI) as a result of patent expiry of drugs, focus of government and non-profit organizations on creating awareness about anemia, research and development grants, and tax credits offered.

Based on drug type, the epoetin beta therapeutics market has been segmented into biologics and biosimilars. The biologics segment dominated the epoetin beta therapeutics market in 2016. However, epoetin beta therapeutics segment is anticipated to expand at a slow pace during the forecast period, as patents for biologic drugs have recently expired and biosimilar drugs for epoetin beta are being made available in the epoetin beta therapeutics market in a few countries. The biosimilars segment is expected to register a rapid growth rate during the forecast period, owing to the reduced cost of biosimilar drugs as compared to biologics. Based on distribution channel, the epoetin beta therapeutics market has been segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the epoetin beta therapeutics market in 2016 and is anticipated to remain dominant during the forecast period as well. The online pharmacy segment is anticipated to expand at a significantly high CAGR during the forecast period, owing to factors such as extending reach of online pharmacies to customers, rising availability of Internet facilities globally, and other services such as cost containment offered by online pharmacies. 

Geographically, the global epoetin beta therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global epoetin beta therapeutics market in 2016 and is anticipated to remain dominant during the forecast period also. Growth of the epoetin beta therapeutics market in the region can be attributed to the increasing number of approvals of erythropoietin drugs and incentives offered for research on chronic kidney diseases by governments in the region.

Europe is expected to follow the North America region during the forecast period. Growth of the epoetin beta therapeutics market in the Europe region can be attributed to the rising prevalence of chronic diseases in the region. The epoetin beta therapeutics market in Asia Pacific is expected to expand at the highest CAGR during the forecast period. High rate of incidence of hematological diseases in countries such as India, China, Bangladesh, and Pakistan is likely to drive the epoetin therapeutics market in Asia Pacific between 2017 and 2025.

Major players operating in the global epoetin therapeutics market include Roche, Haemato Pharm, F. Hoffmann-La Roche Ltd., and Bosnia & Herzegovina.

The report offers a comprehensive evaluation of the epoetin beta therapeutics market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the epoetin beta therapeutics market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and epoetin beta therapeutics market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent epoetin beta therapeutics market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Have query on this report?

Make an Enquiry

Success Stories

Our Clients

Tell Us What You Need and We’ll Get Back with the Best Solutions Available.

*
*
*

get in touch

Location :

State Tower, 90 State Street, Suite 700, Albany NY - 12207, United States

Call Us :

US/Canada toll free : 866-997-4948

Tel : +1-518-621-2074